For pharmaceutical companies, a regulatory violation has always carried consequences. But in Alabama the potential financial consequences of discipline are about to become much more significant.
The Alabama State Board of Pharmacy has adopted new civil penalty schedules and a revised penalty methodology that substantially change how monetary penalties may be assessed against regulated entities. The new rules were adopted without changes following the Board’s rulemaking process and are scheduled to become effective October 15, 2026.
For manufacturers, distributors, pharmacies, and other entities operating under Alabama Board of Pharmacy oversight, this is not simply an administrative update. It is another sign of a broader regulatory reality facing the pharmaceutical industry: states are increasingly focused on enforcement, and they are giving themselves stronger tools to make noncompliance more expensive.
Or as one of our clients put it, something else to put the fear of God in you.
From a Flat Cap to a More Sophisticated Penalty Framework
The significance of Alabama’s new framework becomes clearer when compared with the previous law.
Under the former statutory authority, the Board could impose penalties of up to $1,000 for each violation. Act 2025-372 repealed that authority and replaced it with a framework requiring the Board to establish dollar ranges based on the underlying violation and differentiated by categories of licensees, including chain pharmacies, independent pharmacies, manufacturers, and distributors.
The Alabama State Board of Pharmacy has now implemented that framework through new Chapter 680-X-A and amendments to Rule 680-X-2-.50. Rather than relying on a single flat per-violation cap, the new system establishes specific penalty ranges for particular violations and license categories.
The Board also adopted what it describes as a “lodestar” methodology to structure how it considers the level and scope of misconduct, the risk to public health and safety, and the compliance history of the violator when determining a civil penalty.
That distinction matters. Alabama is moving toward a system in which the potential consequences of a disciplinary matter are more closely tied to the nature of the violation, the circumstances surrounding it, and the Board’s assessment of risk and prior compliance.
The Potential Exposure Is Significantly Higher
The new schedules contain penalty ranges that can reach well beyond the former $1,000-per-violation cap.
Depending on the license category and underlying conduct, the schedules include potential penalties ranging from several thousand dollars to tens of thousands of dollars. For example, the schedules include penalties of up to $10,000 for certain recordkeeping violations, up to $25,000 for certain violations involving laws regulating the sale or dispensing of prescription drugs, and up to $50,000 for certain activities involving sterile products without required certification.
The schedules also include separate civil penalty provisions for manufacturers and distributors, reflecting the Legislature’s direction that penalty ranges be differentiated by license category.
This does not mean every violation will result in the maximum penalty. In fact, the Board has stated that the ranges are intended to preserve discretion, including the ability to impose no civil penalty in cases where a penalty is not considered appropriate. But the ceiling has changed dramatically, and the consequences of serious or repeated noncompliance can now be substantially greater.
Compliance History Can Become Part of the Equation
One particularly important aspect of Alabama’s new approach is the role of compliance history.
The statute directs the Board to consider the compliance history of the violator as part of its penalty determination, alongside the level and scope of misconduct and the level of risk to public health and safety. The Board has also clarified that compliance history attaches to the specific permit or license holder found to have committed the violation.
The practical lesson for pharmaceutical companies is straightforward. Compliance problems should not be viewed in isolation.
A company that treats a warning, administrative fine, or disciplinary issue as a one-time inconvenience may not fully appreciate how its compliance history could affect future enforcement exposure. Maintaining a strong record of regulatory compliance is increasingly important not only for avoiding immediate discipline, but also for reducing the potential consequences if a future issue arises.
A Larger Trend Worth Watching
Alabama’s changes are especially notable because they reflect a broader direction in state pharmaceutical regulation.
The complexity of pharmaceutical compliance has never been limited to obtaining a license and remembering to renew it. Companies must continually monitor changing requirements, understand how those changes apply to their specific operations, and recognize that the consequences of getting it wrong can change just as quickly as the regulations themselves.
States are actively refining their enforcement frameworks, clarifying their authority, expanding their expectations, and, in cases like Alabama, increasing the financial consequences available when companies operate out of compliance.
That creates a dangerous gap for companies relying on a reactive compliance strategy.
By the time a regulatory change becomes widely known throughout an organization, the state may already expect companies to be operating under the new requirement. And when the potential penalties become higher, the cost of being caught off guard increases with them.
The new Alabama rules are a reminder that state licensing compliance is not a static function. The rules that applied when a company obtained its license may not be the rules that apply today.
What This Means for Pharmaceutical Companies
Manufacturers and distributors with Alabama licenses should pay particular attention to how the new schedules apply to their operations. Pharmacies are also directly affected, with separate schedules for chain pharmacies, independent pharmacies, and other pharmacy types. The new Chapter 680-X-A itself reflects how detailed and violation-specific the penalty framework has become.
But this development also carries a larger message for pharmaceutical companies operating in multiple states.
No company can effectively manage compliance by looking at each state only once a year or waiting until a license renewal is approaching. Regulatory changes can affect licensing obligations, operational requirements, reporting responsibilities, disciplinary exposure, and the financial consequences of a violation.
A manufacturer may need to evaluate a change differently than a wholesale distributor. A virtual manufacturer may face a different licensing analysis than a company that physically manufactures and distributes product. The products involved, the company’s distribution model, the states in which it operates, and the licenses it holds can all determine whether a new regulatory development is relevant.
That is why regulatory monitoring must be connected to the realities of a company’s business model.
Compliance Updates Built Around What Actually Impacts Your Business
At SLS, our in-house legal and compliance teams continuously track regulatory and licensing changes at the state level on behalf of our clients.
But monitoring a new rule is only the first step.
The real value is determining whether that change actually impacts a client’s operations. Our teams analyze regulatory developments based on each client’s business model, product line, the states in which they operate, and the licenses they hold. When a development is relevant, we inform the client through our Compliance Updates so they can understand what changed and evaluate the potential impact before the issue becomes an enforcement problem.
That approach is especially important as states continue to become more active in both enforcement and rulemaking.
A generic regulatory alert is easy to ignore. A compliance update that identifies a change in a state where your company is licensed, explains how it may affect the products you distribute or manufacture, and gives your team the information needed to respond is something very different.
It turns regulatory noise into actionable intelligence.
The Cost of Falling Behind Is Increasing
Alabama’s new civil penalty framework is ultimately about more than higher numbers on a schedule.
It demonstrates how quickly the risk profile of operating out of compliance can change. A company may have the same license, conduct the same business, and operate in the same state, yet face a substantially different enforcement environment because the state has changed how it approaches penalties.
That is why compliance cannot be treated as a checklist completed at renewal time.
The companies best positioned to manage regulatory risk are the ones that know what is changing, understand how those changes apply to their operations, and have a process for responding before a regulator identifies the problem for them.
Alabama has raised the stakes. Other states will continue to refine their own regulations and enforcement approaches.
For pharmaceutical companies, the message is becoming increasingly clear: staying licensed is important. Staying current is essential.
SLS helps pharmaceutical companies stay ahead of state licensing and regulatory changes with ongoing monitoring, experienced legal and compliance teams, and Compliance Updates tailored to the realities of each client’s business. Contact our team to learn how we can help turn regulatory complexity into clarity.